Diagnose causation of acute lower respiratory infections, such as Community Acquired Pneumonia and Exacerbations in patients with Chronic Respiratory Disease.
Providing a sample from the site of infection, allowing for diagnostic results within the "golden" hour, enabling directed therapy in a timely fashion.
Proof-of-Concept study 2019; Assessment of COPD patients admitted to the hospital with an exacerbation.
Early detection of respiratory pathogens in patients with Chronic Respiratory Disease, e.g. CF and COPD.
Easy-of-use and low sampling burden allow for daily or even hourly sampling, enabling health monitoring of the lower respiratory tract and early treatment, avoiding under- or over-treatment and herewith exacerbations.
Early causation in CF patients; Published in Journal of Breath Research, 2022.
More relevant than ever, safeguarding medical personnel and determining if a patient should be isolated or can go home to recover.
The presence of pathogens, e.g. Mycobacterium tuberculosis or SARS-COV-2, does not determine contagiousness, bio-loaded aerosols do.
Determining contagiousness of COVID-19 patients by sampling exhaled breath; Published in Scientific Reports, 2022.
Leave us a message
Xheal Diagnostics B.V. is a start-up company and spin-off of the Radboudumc focussed sampling innovations for the lower respiratory tract. Our proprietary exhaled breath sampling technology enables a timely and better diagnosis of lung infections and hence improves patient care.